PEPG · PepGen Inc.
Market Cap
$179.38M
Shares
69.26M
Volume · Oct 5
606.17K
Avg daily vol (3M)
1M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.28
Open$2.24
Day$2.23–2.31
52W close$1.35–7.17
Avg vol 30d782K
Short int3.9M · 5.6% float · 5.2d
Short vol37%
Last earningsMar 30, 2026
DataMay 2022–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Mar 20, 2027
Est · unconfirmed
· in 24 wks
filed Aug 6, 2026
call held Mar 6, 2024
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$71.94M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$117.24M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+111.3%
Year over year · more shares
Price change (1Y)
-55.1%
Trailing year
Short interest
5.6%
Latest settlement · 5.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Neutral
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−33%
below
Price vs 50-day avg
−16%
below
RSI (14)
34
neutral
MACD trend
Negative
52-week position
16%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−28%
trailing
6-month return
+35%
trailing
YTD return
−65%
this year
Relative strength
+23%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-25% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.59% of float · ▲ +4.8% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
71 holders — mid 3-yr range
Squeeze score
60
elevated · 0–100
Fundamentals
EPS growth
+26%
Y/Y
Free cash flow
$-81.9M
Quant / Vol
risk profile
Volatility
108%
annualized · 1-yr
Max drawdown
−81%
past year
ATR
8.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−33%
Bearish
Price vs 50-day avg
−16%
Bearish
RSI (14)
34
Neutral
MACD trend
Negative
Bearish
52-week position
16%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-25% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.59% of float · ▲ +4.8% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
71 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $2 · 16%
Range high $7
vs 200-day avg -33%
vs 50-day avg -16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| FREEDOM2 10 mg/kg cohort participants dosed | 7 | Q2 2026 | — |
| OLE total enrollment | 16 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PEPG
this stock
PepGen Inc.
|
$179.38M | -65.0% | — | — | 5.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PEPG | -12.0% | -28.3% | +34.9% | -5.8% | -65.0% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -11.8% | -27.8% | +22.7% | -6.7% | -77.8% |